Edition:
United States

Galectin Therapeutics Inc (GALTU.OQ)

GALTU.OQ on NASDAQ Stock Exchange Capital Market

4.19USD
14 Jan 2016
Change (% chg)

-- (--)
Prev Close
$4.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$10.77
52-wk Low
$3.70

GALTU.OQ

Chart for GALTU.OQ

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $40.99
Shares Outstanding(Mil.): 29.28
Dividend: --
Yield (%): --

Financials

  GALTU.OQ Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -0.89 -- --
ROI: -116.18 -0.27 13.98
ROE: -197.66 -2.93 14.88

BRIEF-Galectin says announces top-line data from exploratory phase 2A pilot trial (NASH-FX)

* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis

Sep 27 2016

BRIEF-Galectin Therapeutics posts results from extended psoriasis clinical trial - SEC Filing

* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing

Aug 25 2016

BRIEF-Galectin Therapeutics Q2 loss per share $0.20

* Galectin therapeutics reports second quarter 2016 financial results and provides business update

Aug 09 2016

BRIEF-Galectin Therapeutics quarterly loss per share $0.20

* Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017

Aug 09 2016

BRIEF-Galectin Therapeutics reports positive mid-stage data on psoriasis drug

* Two adverse events were noted, one infiltration of intravenous catheter & one headache during infusion; were mild & transient

May 16 2016

BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug

* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis

May 11 2016

BRIEF-Galectin Therapeutics Inc qtrly loss per share $0.24

* Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017

May 10 2016

BRIEF-Galectin Therapeutics reports Q1 loss $0.24/shr

* Galectin Therapeutics reports first quarter 2016 financial results and provides business update

May 10 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF77.25 -1.30
Merck & Co., Inc. (MRK.N) $61.91 -1.39
Roche Holding Ltd. (ROG.S) CHF241.80 -2.80
Roche Holding Ltd. (RO.S) CHF242.90 -2.00
Eli Lilly and Co (LLY.N) $79.74 -0.97
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $11.39 -0.42

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.